The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1722
February 17, 2025
View Complete Issue         Table of Contents 2019 
Nemolizumab (Nemluvio) for Atopic Dermatitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Nemolizumab (Nemluvio) for Atopic Dermatitis
February 17, 2025 (Issue: 1722)
Nemolizumab (Nemluvio – Galderma), a subcutaneously injected interleukin-31 (IL-31) receptor antagonist, has been approved by the FDA for use in combination with topical corticosteroids and/or calcineurin inhibitors for treatment of moderate to...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Nemolizumab (Nemluvio) for Atopic Dermatitis
Article code: 1722a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.